Clinical Trial Update: Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLL [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the efficacy of acalabrutinib in very old or frail patients with treatment-naïve or relapsed/refractory chronic lymphocytic leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• CALQUENCE (ACALABRUTINIB)

Snippet

Sponsor: German CLL Study Group | Conditions: Chronic Lymphoid Leukemia | Phase 2 | Status: COMPLETED